Vaccines in the management of hypertension

Expert Opinion on Biological Therapy

Volumn 10, Issue 7, 2010, Pages 1077-1087

  Do, Thong Huy ^a   Chen, Yijia ^a   Nguyen, Van T ^a   Phisitkul, Sorot ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiotensin; Angiotensin I; Angiotensin II; Angiotensin II receptor; Hypertension; Immune drug; Renin; Vaccine

Indexed keywords

ALISKIREN; ALUMINUM HYDROXIDE; ANGIOTENSIN 1 RECEPTOR VACCINE; ANGIOTENSIN I; ANGIOTENSIN I KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; ANGIOTENSIN I TETANUS TOXOID CONJUGATE VACCINE; ANGIOTENSIN I VACCINE; ANGIOTENSIN II VACCINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATR12181 VACCINE; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CYT006 ANGQB VACCINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FREUND ADJUVANT; HYPERTENSION VACCINE; IRBESARTAN; KEYHOLE LIMPET HEMOCYANIN; LOSARTAN; PLACEBO; PMD 2850; PMD 3117; RAMIPRIL; RENIN; RENIN ANTIBODY; RENIN VACCINE; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIBODY TITER; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ERYTHEMA; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE REACTION; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SKIN INDURATION; SKIN NODULE; SWELLING;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTENSION; OLIGOPEPTIDES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VACCINES;

ANIMALIA;

EID: 77953330160     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.487060     Document Type: Review

References (65)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003;42:1206-1252
2. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-827
3. Cherry DK, Hing E, Woodwell DA, Rechtsteiner EA. National ambulatory medical care survey: 2006 summary. Natl Health Stat Rep 2008;3:1-39
4. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women. Hypertension 2005;46:280-286
5. U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007;147:783-786
6. Vikrant S, Tiwari SC. Essential hypertension - pathogenesis and pathophysiology. J Indian Acad Clin Med 2001;2:140-161
7. Deng AY. Genetic basis of polygenic hypertension. Hum Mol Genet 2007;16:R195-R202
8. Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003;21:37-42
9. Torp-Pedersen C, Kober L, Carlsen J. Angiotensin-converting enzyme inhibition after myocardial infarction: the trandolapril cardiac evaluation study. Am Heart J 1996;132:235-243
10. Cohn JN. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in heart failure trial. Cardiology 1999;91(Suppl 1):19-22
11. Shahinfar S, Dickson TZ, Ahmed T, et al. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. Kidney Int Suppl 2002;82:S64-S67
12. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy. J Am Soc Nephrol 2001;12:2832-2837
13. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041
14. Bühler FR, Bolli P, Kiowski W, et al. Renin profiling to select antihypertensive baseline drugs. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984;77(2A):36-42
15. Laragh JH, Resnick LM. Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Int Suppl 1988;25:S162-S174
16. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009;22:112-121
17. Goldblatt H, Haas E, Lamfrom H. Antirenin in man and animals. Trans Assoc Am Physicians 1951;64:122-125
18. Frank MH. Renin in experimental renal hypertension in monkeys. Circ Res 1963;12:241-255
19. Hartroft PM. Juxtaglomerular cells. Circ Res 1963;196:525-538
20. Michel JB, Guettier C, Philippe M, et al. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci USA 1987;84:4346-4350
21. Reade R, Michel JB, Carelli C, et al. Immunization of spontaneously hypertensive rats against angiotensin 1. Arch Mal Coeur Vaiss 1989;82:1323-1328
22. Downham MR, Auton TR, Rosul A, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003;56:505-512
23. LeClerc C, Schutze MP, Deriaud E, Przewlocki G. The in vivo elimination of CD4+ cells prevents the induction but not the expression of carrier-induced epitopic suppression. J Immunol 1990;145:1343-1349
24. Brown MJ, Coltart J, Gunewardena K, et al. Randomized double-blind placebocontrolled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004;107:167-173
25. Brookes L. New antihypertensive therapies and old hypertensive risks?. Medscape cardiology. Published online: 17 April 2008. Available from: http:// www.medscape.com/viewarticle/572933 [Last accessed 23 April 2010].
26. Johnston CI, Hutchinson JS, Mendelsohn FA. Biological significance of renin-angiotensin immunization. Circ Res 1970;26(Suppl II):215-222
27. Macdonald GJ, Louis WJ, Renzini V, et al. Renal-clip hypertension in rabbits immunized against angiotensin II. Circ Res 1970;27:197-211
28. Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993;262:1448-1451
29. Jegerlehner A, Tissot F, Lechner P, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002;20:3104-3112
30. Lechner F, Jegerlehner A, Tissot AC, et al. Virus-like particles as a modular system for novel vaccines. Intervirology 2002;45:212-221
31. Goodnow CC, Adelstein S, Basten A. The need for central and peripheral tolerance in the B cell repertoire. Science 1990;248:1373-1379
32. Jennings GT, Bachmann MF. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med 2007;7:143-155
33. Ambühl PM, Tissot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007;25:63-72
34. Tissot AC, Maurer P, Nussberger J, et al. Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008;371:821-827
35. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-743
36. Zhu F, Liao YH, Li LD, et al. Target organ protection from a novel angiotensin II receptor (AT-1) vaccine ATR 12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006;3:107-114
37. Feng Z, Yu-Hua L, Liudong L. Observation of long-term efficacy and safety of an ATR12181 vaccine against hypertension in SHR [abstract 2753]. Circulation 2006;114:II 575
38. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472
39. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic antibodies against the angiotension AT1 receptor. J Clin Invest 1999;103:945-952
40. Li LD, Liao YH, Zhou ZH, et al. Effects of active immunization with agiotensin II receptor type 1 peptides on blood pressure and cardiovascular remodeling in spontaneous hypertensive rats. Zhongguo Mian Yi Xue Za Zhi 2005;21:372-376
41. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-757
42. Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009;49:303-326
43. Verdier F. Non-clinical vaccine safety assessment. Toxicology 2002;174:37-43
44. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-1529
45. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001;4:751-755
46. Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005;35:2031-2040
47. Lindblad E. Aluminium adjuvants in retrospect and prospect. Vaccine 2004;22:3658-3668
48. Paul S, Kenny AB, Hitzig WH. Immune response to keyhole-limpet hemocyanin in the human. Int Arch Allergy Appl Immunol 1974;47:155-160
49. LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009;54:905-909
50. Dechend R, Müller DN, Wallukat G, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol 2004;24:571-579
51. Nydegger UE. Immune complex pathophysiology. Ann NY Acad Sci 2007;1109:66-83
52. Janin J, Cothia C. The structure of protein-protein recognition sites. J Biol Chem 1990;265:16027-16030
53. Van Regenmortel MHV. Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity. Methods 1996;9:465-472
54. Gilman S, Koller M, Black RS, et al. Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562
55. Wakerlin GE. Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation 1958;17:653-657
56. Weiser RA, Johnson AG, Hoober SW. The effect of antirenin on the blood pressure of the rat with experimental renin hypertension. Lab Invest 1969;20:326-331
57. Hill RW, Chester JE, Wisenbaugh PE. The effect of intravenous antirenin injection on chronic experimental and acute renin induced hypertension in dogs. Lab Invest 1970;22:404-416
58. Romero JC, Hoober SW, Kozak TJ, Warzymski RJ. Effect of antirenin on blood pressure of rabbits with experimental renal hypertension. Am J Physiol 1973;225:810-817
59. Skeggs LT, Kahn JR, Levine M, et al. Chronic one-kidney hypertension in rabbit. Circ Res 1975;7:715-724
60. Slater EE, Corvol P, Menard J, et al. Antisera to human renin normalizes renin-dependent hypertension in the monkey: therapeutic implications. Clin Exp Hypertens 1984;A6:923-937
61. Wood JM, Feusser C, Gulati N, et al. Monoclonal antibodies against human renin: blood pressure effect in the marmoset. Hypertension 1986;8:600-605
62. Katz J, Skom JH, Walkerlin G. Pathogenesis of spontaneous and pyelonephritic hypertension in dog. Circ Res 1957;5:137-143
63. Helmer M. Studies on renin antibodies. Circulation 1958;17:648-652
64. Deodhar SD, Haas E, Goldblatt H. Production of antirenin to homologous renin and its effect on experimental renal hypertension. J Exp Med 1964;139:425-435
65. Michel JP, Galen FX, Guettier C, Sayah S. Immunological approach to blockade of the renin-substrate reaction. J Hypertens Suppl 1989;7(2):S63-70